Policy positions and statements

At Hikma, we help improve lives by providing patients with access to high-quality and affordable medicines.

Learn about our policies across a range of issues that are important to Hikma, healthcare professionals, patients, and our stakeholders.

The objective of Hikma's Board Diversity Policy is to ensure that the Board is an inclusive place that welcomes different cultures, perspectives, and experiences from across the globe.

Hikma is committed to engaging talented people, irrespective of their race, colour, religion, age, sex, sexual orientation, marital status, national origin, present or past history of mental or physical disability, socio-economic background and any other factors not related to a person's ability to perform the relevant role.

Board Diversity Policy

We are focused on ensuring our organisation is resilient to disruptive events so that we can maintain a consistent and reliable supply of high-quality medicines for our customers, healthcare professionals and the patients they care for.

Crisis and Continuity Management Statement

Hikma is committed to helping solve drug shortages, which unfortunately are occurring with increasing frequency across the global markets we serve.

Drug Shortages Statement

As a leading global pharmaceutical company whose purpose is putting better health within reach every day, Hikma is committed to providing our employees with a safe and healthy workplace.

Group Environmental, Health And Safety Policy Statement (Feb 2024)

Our annual Modern Slavery Act statement, as required by the Modern Slavery Act 2015 (“the Act”), provides details on the controls we have adopted to ensure that modern slavery and human trafficking do not take place in our supply chain or in any part of our business.

Modern Slavery Statement 2023

Modern Slavery Statement 2022

Modern Slavery Statement 2021

Modern Slavery Statement 2020

Modern Slavery Statement 2018

When required by regulatory authorities to conduct animal testing as part of new drug development, we only outsource to partners with the highest ethical standards.

When it is necessary to use animals in the development or production of new medicinal products, we are committed to their humane and ethical treatment. More specifically, our commitment to humane animal testing and enhanced welfare is guided by the principle of the three Rs:

1. Replacement
Using methods which avoid or replace the use of animals in research.

2. Reduction
Using methods that deliver comparable levels of information from fewer animals or to obtain more information from the same number of animals

3. Refinement
Using methods that alleviate or minimise potential pain, suffering or distress, and enhance animal welfare.

Hikma aims to improve lives by providing patients with access to high quality, affordable medicines. Our medicines are used thousands of times a day around the world to treat illness and save lives.

We object in the strongest possible terms to the use of any of our Products for the purpose of Capital Punishment. Not only is it contrary to the intended label use(s) for the Products, but it is also inconsistent with our values and mission of improving lives by providing quality, affordable healthcare to patients.

While none of our Products should ever be used for the purpose of Capital Punishment, set forth below, we have identified certain product-families that carry heightened risk of misuse for lethal injection protocols. Accordingly, to prevent these Products from these product-families being used for the purpose of Capital Punishment, we will not accept orders for Products from these product-families directly from any Departments of Correction or correctional facilities in the United States, unless accompanied by an original, raised seal copy of an affidavit signed by the state Attorney General (or Governor), certifying under penalty of perjury that the Product(s) will not be used for Capital Punishment. Further, we will only sell these Products to pre-selected commercial customers who agree that they will not then sell or provide them to: (i) Departments of Corrections; (ii) correctional facilities; (iii) secondary distributors; or (iv) retail pharmacies.

Hikma vigorously monitors the distribution of these Products and support industry serialisation efforts that will help enhance these controls while continuing to promote our values and mission.

Transparency is one of our core values, and as such Hikma also objects to attempts by any entity, person or state to obscure or hide the source of Products for lethal injection. It is imperative that we are not impeded from protecting patient health and the integrity of our Products and our supply chain.

PRODUCT-FAMILY NAME